Published in Osteoporos Int on April 14, 2012
Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 1.15
Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int (2015) 0.86
Marrow fat and bone: review of clinical findings. Front Endocrinol (Lausanne) (2015) 0.86
Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol (2014) 0.84
Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int (2014) 0.83
Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res (2013) 0.83
Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab (2013) 0.82
Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab (2013) 0.80
Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. Arthritis Res Ther (2014) 0.80
Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab (2014) 0.78
Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab (Seoul) (2014) 0.77
Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J (2015) 0.77
Sclerostin serum levels in patients with systemic autoimmune diseases. Bonekey Rep (2016) 0.76
Has sclerostin a true endocrine metabolic action complementary to osteocalcin in older men? Osteoporos Int (2016) 0.76
The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int (2016) 0.76
Serum sclerostin levels in renal cell carcinoma patients with bone metastases. Sci Rep (2016) 0.75
Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses (2015) 0.75
Sclerostin as a novel marker of bone turnover in athletes. Biol Sport (2016) 0.75
Hormonal and systemic regulation of sclerostin. Bone (2016) 0.75
Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. Biomed Res Int (2017) 0.75
Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry. J Bone Metab (2016) 0.75
Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study. Osteoporos Int (2016) 0.75
24-hour profile of serum sclerostin and its association with bone biomarkers in men. Osteoporos Int (2017) 0.75
The Utility of Biomarkers in Osteoporosis Management. Mol Diagn Ther (2017) 0.75
Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults. Osteoporos Int (2017) 0.75
Association of circulating dipeptidyl-peptidase 4 levels with osteoporotic fracture in postmenopausal women. Osteoporos Int (2016) 0.75
Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res (1993) 10.98
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
The amazing osteocyte. J Bone Miner Res (2011) 5.32
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med (2004) 3.88
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res (2011) 3.25
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res (2010) 2.19
Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab (2010) 2.05
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res (2007) 1.74
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res (1997) 1.42
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int (2011) 1.23
Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res (2011) 1.23
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol (2007) 1.19
Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab (2011) 0.99
Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab (2011) 0.96
Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab (2011) 0.96
X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. Nat Genet (1996) 3.90
Spontaneous skin ulceration and defective T cell function in CD18 null mice. J Exp Med (1998) 2.81
Risk factors of obesity in a five year old population. Parental versus environmental factors. Int J Obes Relat Metab Disord (1992) 2.80
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem (1998) 2.48
A model for enhancing Internet medical document retrieval with "medical core metadata". J Am Med Inform Assoc (1999) 2.37
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res (2000) 2.24
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res (2003) 1.68
Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone (2003) 1.54
Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res (1997) 1.42
Health Research Profile to assess the capacity of low and middle income countries for equity-oriented research. BMC Public Health (2006) 1.33
Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab (2001) 1.30
Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet (2000) 1.28
Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone (2006) 1.27
The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone (2002) 1.26
[Fetal growth from the AUDIPOG study. I. Establishment of reference curves]. J Gynecol Obstet Biol Reprod (Paris) (1996) 1.20
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2010) 1.19
Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res (1999) 1.19
Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int (2012) 1.19
Collagen Ialpha1 Sp1 polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. J Bone Miner Res (1998) 1.13
The association between occupational factors and preterm birth: a United States nurses' study. Research Committee of the Association of Women's Health, Obstetric, and Neonatal Nurses. Am J Obstet Gynecol (1995) 1.09
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 1.07
Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int (2000) 1.04
Cortical and trabecular architecture are altered in postmenopausal women with fractures. Osteoporos Int (2009) 1.03
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int (2011) 1.03
Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochem J (2000) 1.02
Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density. J Clin Endocrinol Metab (2005) 1.01
A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1. Br J Cancer (2006) 1.00
Ultrasound measurements on os calcis: precision and age-related changes in a normal female population. Osteoporos Int (1993) 0.98
Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res (2001) 0.98
Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem (2001) 0.96
Occupational working conditions and preterm birth: a reliable scoring system. Am J Epidemiol (1987) 0.95
Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab (2014) 0.95
Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int (2007) 0.94
Vitamin D receptor gene polymorphisms do not predict bone turnover and bone mass in healthy premenopausal women. J Bone Miner Res (1995) 0.94
Quantification of immature and mature collagen crosslinks by liquid chromatography-electrospray ionization mass spectrometry in connective tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.92
[Fetal growth from the AUDIPOG study. II. Application for the diagnosis of intrauterine growth retardation]. J Gynecol Obstet Biol Reprod (Paris) (1996) 0.91
Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study. Calcif Tissue Int (2003) 0.91
Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS study. Osteoporos Int (2001) 0.90
Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int (2010) 0.89
Scarcity of mutations detected in families with X linked hypohidrotic ectodermal dysplasia: diagnostic implications. J Med Genet (1998) 0.89
A routine assay for the direct analysis of HLA-DR-related shared epitope and B27 alleles in chronic inflammatory arthritis. J Immunol Methods (2001) 0.89
Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study. Bone (2002) 0.88
Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 0.88
Assessment of vertebral fracture using densitometric morphometry. J Clin Densitom (2005) 0.87
Pregnant women at work: rest periods to prevent preterm birth? Paediatr Perinat Epidemiol (1989) 0.86
Age-related changes in Os calcis ultrasonic indices: a 2-year prospective study. Osteoporos Int (1995) 0.86
Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol (R Coll Radiol) (2010) 0.85
Decreased bone turnover in oral contraceptive users. Bone (1995) 0.85
Equation or algorithm: differences and choosing between them. Acta Biotheor (2010) 0.85
Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: the OFELY Study. J Bone Miner Res (1996) 0.85
Association between collagen cross-links and trabecular microarchitecture properties of human vertebral bone. Bone (2009) 0.84
Severity of aortic calcification is positively associated with vertebral fracture in older men--a densitometry study in the STRAMBO cohort. Osteoporos Int (2012) 0.84
An in vitro model to test the contribution of advanced glycation end products to bone biomechanical properties. Bone (2007) 0.83
Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study. Eur J Endocrinol (2011) 0.82
Transvaginal ultrasonography of the uterine cervix in hospitalized women with preterm labor. Int J Gynaecol Obstet (2001) 0.82
Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res (2002) 0.82
Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos Int (2009) 0.81
[Measurement of bone density in the wrist using X-ray absorptiometry: comparison with measurements of other sites]. Rev Rhum Ed Fr (1994) 0.81
Local topological analysis at the distal radius by HR-pQCT: Application to in vivo bone microarchitecture and fracture assessment in the OFELY study. Bone (2012) 0.81
FRAX® probabilities and risk of major osteoporotic fracture in France. Osteoporos Int (2011) 0.79
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. Anticancer Res (2012) 0.79
How to predict fragility fracture beyond 10 years? The OFELY study. J Clin Endocrinol Metab (2014) 0.78
Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature. Br J Cancer (2013) 0.78
Comparison of morphometric assessment of prevalent vertebral deformities in women using different reference data. Bone (2000) 0.78
Development and use of a self-administered questionnaire for assessment of psychologic attitudes toward pregnancy and their relation to a subsequent premature birth. Am J Epidemiol (1989) 0.78
Impaired trabecular and cortical microarchitecture in daughters of women with osteoporotic fracture: the MODAM study. Osteoporos Int (2012) 0.78
Staining procedure for the detection of microcracks: application to ewe bone. Bone (2011) 0.77
Similar prevalence of vertebral fractures despite different approaches to define reference data. Bone (2003) 0.77
Osteoid osteoma is an osteocalcinoma affecting glucose metabolism. Osteoporos Int (2011) 0.76
Target registration errors with surface imaging system in conformal radiotherapy for prostate cancer: study on 19 patients. Radiol Med (2012) 0.76
What PROOF proves about calcitonin and clinical trials. Am J Med (2000) 0.76
Oral bisphosphonates and risk of ischemic stroke: a case-control study. Osteoporos Int (2010) 0.76
Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma. Anticancer Res (2008) 0.76
Cross-sectional and longitudinal assessment of pre- and postmenopausal bone loss with a portable forearm X-ray device: the Ofely study. Bone (2000) 0.75
Central corneal thickness and intraocular pressure in ocular hypertension. Graefes Arch Clin Exp Ophthalmol (2001) 0.75
Ergotism: an infrequent aetiology of intermittent claudication. Postgrad Med J (1996) 0.75
Effective prevention of preterm birth: the French experience measured at Haguenau. Birth Defects Orig Artic Ser (1989) 0.75
[Life style of children and obesity in a population of 5-year-old children]. Rev Epidemiol Sante Publique (1992) 0.75
[Prevention of prematurity by psychotherapeutic management]. Contracept Fertil Sex (1998) 0.75
[The Association of Computerized Medical Records Users in Perinatology, Obstetrics and Gynecology Sentinel Network for maternity hospitals. I. Perinatal health indicators in 1994]. J Gynecol Obstet Biol Reprod (Paris) (1996) 0.75
Family resemblance of bone turnover rate in mothers and daughters--the MODAM study. Osteoporos Int (2014) 0.75
[Is it possible to improve sleep in children? A research on health education in nursery schools]. Arch Pediatr (1997) 0.75
[Re-biopsies of the prostate after endo-magnetic resonancen imaging (MRI) and spectroscopy (MRS) in patients with ASAP: preliminary results]. Urologia (2009) 0.75
Prevention of preterm birth in patients with symptoms of preterm labor--the benefits of psychologic support. Am J Obstet Gynecol (1997) 0.75
Obsessional symptoms in expectant women and outcome of their pregnancy. J Psychosom Obstet Gynaecol (1994) 0.75
[The Association for Computerized Medical Records Users in Perinatology, Obstetrics and Gynecology sentinel network for maternity hospitals. II. Changes in practices and results. 1994-1997]. J Gynecol Obstet Biol Reprod (Paris) (1998) 0.75